Latest Breaking News On - Katie lunnon - Page 1 : vimarsana.com

Diego Mastroeni, assistant research professor at ASU s Banner Neurodegenerative Disease Research Center. The onset and advancement of Alzheimer’s disease (AD) is affected not only by a patient’s genes but also by the molecular switches that turn them on and off. Now, one of the largest studies of these controls, know collectively as the epigenome, offers scores of possible AD treatment targets. The meta-study, led by Katie Lunnon of the University of Exeter Medical School in the United Kingdom, appears in the journal Nature Communications. Co-author Diego Mastroeni of the ASU-Banner Neurodegenerative Disease Research Center says the epigenome is a promising treatment toolkit because it’s far easier to manipulate than DNA.

United kingdomKaely monahanDiego mastroeniKatie lunnonUniversity of exeter medical schoolNature communicationsBanner neurodegenerative disease research centerNeurodegenerative disease research centerExeter medical schoolஒன்றுபட்டது கிஂக்டம்கேடீ லன்னன்பல்கலைக்கழகம் ஆஃப் எக்ஸெடர் மருத்துவ பள்ளிஇயற்கை தகவல்தொடர்புகள்எக்ஸெடர் மருத்துவ பள்ளி